Immunocore Holdings plc (IMCR) Stock Analysis and Metrics

Immunocore Holdings

NASDAQ: IMCR

$35.02 ▼ -0.49 (-1.38%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap1.78 Bn

P/E-64.48

P/S4.31

Div. Yield0.00

Total Debt (Qtr)393.66 Mn

Revenue Growth (1y) (Qtr)13.63

Add ratio to table…

About

Immunocore Holdings plc is a commercial stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX® platform, the company develops a deep pipeline across these therapeutic areas, including clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease, and earlier pre-clinical programs.

Immunocore Holdings plc generates revenue primarily from the sale of its approved product, KIMMTRAK (tebentafusp), for the treatment of unresectable or metastatic uveal melanoma. The company commercializes KIMMTRAK through a hybrid model featuring an in-house sales force in the United States and contracted resources in the United States and Europe, supported by distribution partners such as Medison Pharma Ltd. for select international regions and Er-Kim Pharmaceuticals Bulgaria EOOD for territories including Turkey, the Middle East, and North Africa. Revenue is derived from product sales to healthcare providers and institutions treating eligible patients.

The company operates through the following segments: ImmTAC (Oncology), ImmTAV (Infectious Diseases), and ImmTAAI (Autoimmune Diseases).

• ImmTAC: This segment focuses on oncology, developing ImmTAC molecule candidates that target cancer-specific antigens. Key programs include KIMMTRAK (tebentafusp) which is approved for uveal melanoma and in Phase 3 trials for cutaneous melanoma, brenetafusp which is a PRAME-targeted candidate in Phase 3 trials for melanoma and Phase 1/2 for ovarian cancer, and other candidates such as IMC-R117C for gastrointestinal cancers and IMC-P115C for PRAME-positive tumors.

• ImmTAV: This segment addresses infectious diseases, with the lead program IMC-M113V targeting a functional cure for HIV in Phase 1/2 clinical trials, and IMC-I109V for hepatitis B virus, having completed the SAD portion of a Phase 1 trial.

• ImmTAAI: This segment concentrates on autoimmune diseases, developing candidates such as IMC-S118AI for type 1 diabetes targeting pancreatic beta-cells, and IMC-U120AI for atopic dermatitis targeting CD1a on antigen-presenting cells, both advancing toward clinical trials.

Immunocore Holdings plc occupies a distinctive position in the biotechnology industry through its ImmTAX platform, which engineers T-cell receptors to target intracellular proteins inaccessible to conventional antibody-based therapies. This approach provides access to a broader range of disease targets, with competitive advantages including million-fold affinity enhancement over natural TCRs and the ability to modulate immune responses via effector domains. The company faces competition from firms such as Adaptimmune Therapeutics plc, Immatics Biotechnologies GmbH, and others developing TCR-based therapies, but believes its proprietary technology enables treatment of targets with high differential expression between healthy and diseased cells, potentially improving therapeutic index.

Immunocore Holdings plc serves patients with cancer, infectious diseases, and autoimmune diseases through healthcare providers, including oncology centers, hospitals, and specialty clinics. Specific customer names are not disclosed in the filing, but the company collaborates with distribution partners and healthcare systems globally to deliver its therapies to eligible patient populations.

Investment Thesis

▲ Bull case

Immunocore Holdings is positioned for significant revenue expansion beyond its current uveal melanoma base through the successful execution of its Phase 3 life-cycle management trials, particularly TEBE-AM in second-line cutaneous melanoma, which targets a patient population up to four times larger than its current addressable market. Management highlighted that TEBE-AM is the only active Phase 3 trial in this setting with an overall survival endpoint, and if positive, could support pricing parity with its current uveal melanoma therapy due to the demonstrated survival benefit and established safety profile. The company noted that half of all cutaneous melanoma patients are treated by physicians already experienced with KIMTRAK, creating a ready-made commercial infrastructure that could accelerate adoption and reduce launch costs. This existing physician familiarity, combined with the off-the-shelf nature of the therapy, provides a structural advantage over cell-based alternatives like TIL therapy, which faces logistical and accessibility barriers. The real-world data showing a median overall survival of 28 months and one in four patients alive at three years in uveal melanoma validates the platform’s durability and supports confidence in replicating similar outcomes in cutaneous melanoma, where current second-line options offer poor survival prospects. With enrollment on track for completion in 2026 and top-line data expected in the second half of the year, TEBE-AM represents a near-term catalyst that could redefine the company’s growth trajectory and validate the scalability of its TCR platform across solid tumors.
The diversification of Immunocore’s pipeline into infectious disease and autoimmune diseases presents a materially de-risked growth profile that the market is underestimating, supported by early clinical proof-of-concept and regulatory progress. The HIV functional cure program demonstrated a dose-dependent antiviral effect and delayed viral rebound at higher doses in 16 patients, providing preliminary evidence of impact on the viral reservoir—a critical step toward a functional cure—without safety concerns, justifying continued dose escalation in 2026. Simultaneously, the type 1 diabetes autoimmune program has completed its CTA filing in December 2025, with Phase 1 initiation planned for 2026, backed by preclinical data showing S118I binds exclusively to pancreatic beta cells and rescues them from T-cell–mediated killing while preserving insulin secretion. These programs leverage the same TCR platform that has already been validated in oncology, reducing technological risk and enabling cross-indication learnings. The company’s $864 million cash position provides ample runway to advance these programs without near-term financing pressure, and the modular nature of the technology allows for efficient expansion into new therapeutic areas. Success in either infectious disease or autoimmunity would not only diversify revenue streams but also validate the platform’s broad applicability, potentially unlocking partnerships or acquisitions that could significantly enhance long-term valuation beyond current oncology-focused expectations.
Immunocore’s commercial execution in uveal melanoma has established a durable and expanding base that is underappreciated in its contribution to future pipeline launches, with 70% of KIMTRAK prescriptions originating from U.S. community settings and 150 new accounts activated in 2025 alone. This broad community penetration creates a foundational network of physicians experienced with the therapy’s administration, safety monitoring, and patient management—critical factors for successful expansion into cutaneous melanoma indications like TEBE-AM and PRISM-MEL-301. Ralph Torbay emphasized that half of all cutaneous melanoma patients are treated by physicians already familiar with KIMTRAK, meaning the commercial infrastructure for potential new indications is largely pre-built, reducing the time and cost associated with market access and adoption. The company’s real-world evidence generation, including plans to publish U.S. real-world data and share five-year overall survival from the registrational trial, further strengthens differentiation in a market where durable responses are rare. This established physician and patient familiarity, combined with the therapy’s off-the-shelf advantage over autologous alternatives, positions Immunocore to capture share in larger melanoma markets not just based on clinical data, but on operational readiness—a factor often overlooked in early-stage biotech valuations but critical for commercial success.

Immunocore Holdings is positioned for significant revenue expansion beyond its current uveal melanoma base through the successful execution of its Phase 3 life-cycle management trials, particularly TEBE-AM in second-line cutaneous melanoma, which targets a patient population up to four times larger than its current addressable market. Management highlighted that TEBE-AM is the only active Phase 3 trial in this setting with an overall survival endpoint, and if positive, could support pricing parity with its current uveal melanoma therapy due to the demonstrated survival benefit and established safety profile. The company noted that half of all cutaneous melanoma patients are treated by physicians already experienced with KIMTRAK, creating a ready-made commercial infrastructure that could accelerate adoption and reduce launch costs. This existing physician familiarity, combined with the off-the-shelf nature of the therapy, provides a structural advantage over cell-based alternatives like TIL therapy, which faces logistical and accessibility barriers. The real-world data showing a median overall survival of 28 months and one in four patients alive at three years in uveal melanoma validates the platform’s durability and supports confidence in replicating similar outcomes in cutaneous melanoma, where current second-line options offer poor survival prospects. With enrollment on track for completion in 2026 and top-line data expected in the second half of the year, TEBE-AM represents a near-term catalyst that could redefine the company’s growth trajectory and validate the scalability of its TCR platform across solid tumors.
The diversification of Immunocore’s pipeline into infectious disease and autoimmune diseases presents a materially de-risked growth profile that the market is underestimating, supported by early clinical proof-of-concept and regulatory progress. The HIV functional cure program demonstrated a dose-dependent antiviral effect and delayed viral rebound at higher doses in 16 patients, providing preliminary evidence of impact on the viral reservoir—a critical step toward a functional cure—without safety concerns, justifying continued dose escalation in 2026. Simultaneously, the type 1 diabetes autoimmune program has completed its CTA filing in December 2025, with Phase 1 initiation planned for 2026, backed by preclinical data showing S118I binds exclusively to pancreatic beta cells and rescues them from T-cell–mediated killing while preserving insulin secretion. These programs leverage the same TCR platform that has already been validated in oncology, reducing technological risk and enabling cross-indication learnings. The company’s $864 million cash position provides ample runway to advance these programs without near-term financing pressure, and the modular nature of the technology allows for efficient expansion into new therapeutic areas. Success in either infectious disease or autoimmunity would not only diversify revenue streams but also validate the platform’s broad applicability, potentially unlocking partnerships or acquisitions that could significantly enhance long-term valuation beyond current oncology-focused expectations.
Immunocore’s commercial execution in uveal melanoma has established a durable and expanding base that is underappreciated in its contribution to future pipeline launches, with 70% of KIMTRAK prescriptions originating from U.S. community settings and 150 new accounts activated in 2025 alone. This broad community penetration creates a foundational network of physicians experienced with the therapy’s administration, safety monitoring, and patient management—critical factors for successful expansion into cutaneous melanoma indications like TEBE-AM and PRISM-MEL-301. Ralph Torbay emphasized that half of all cutaneous melanoma patients are treated by physicians already familiar with KIMTRAK, meaning the commercial infrastructure for potential new indications is largely pre-built, reducing the time and cost associated with market access and adoption. The company’s real-world evidence generation, including plans to publish U.S. real-world data and share five-year overall survival from the registrational trial, further strengthens differentiation in a market where durable responses are rare. This established physician and patient familiarity, combined with the therapy’s off-the-shelf advantage over autologous alternatives, positions Immunocore to capture share in larger melanoma markets not just based on clinical data, but on operational readiness—a factor often overlooked in early-stage biotech valuations but critical for commercial success.

▼ Bear case

Immunocore Holdings faces growing commercial headwinds in its core KIMTRAK business, as evidenced by slowing sequential quarterly revenue growth in the 4%-7% range, which management explicitly acknowledged is expected to continue declining in 2026 due to high market penetration in major regions. Travis A. Coy noted that the reported 29% year-on-year growth flattered to approximately 20% when normalized for rebate reserves, indicating that underlying demand expansion is weakening faster than topline suggests. With the company now in its fifth year on the market and significant penetration achieved across the U.S. and Europe, the law of large numbers is taking hold, making sustained double-digit growth increasingly difficult without new indication approvals. The reliance on rebate adjustments to mask deceleration raises concerns about the quality of revenue growth, particularly as pricing pressure and payer scrutiny intensify in oncology. Furthermore, while KIMTRAK serves approximately 1,000 metastatic uveal melanoma patients annually, the future addressable population of up to 6,000 patients through ongoing Phase 3 trials remains speculative and contingent on positive trial outcomes—any delay or failure in TEBE-AM or ATOM would significantly delay or diminish this expansion potential, leaving the company overly dependent on a niche indication with limited organic growth runway.
The clinical and regulatory risks associated with Immunocore’s expanding pipeline are underappreciated, particularly given the reliance on early-phase data to justify costly late-stage investments across multiple therapeutic areas. The HIV functional cure program, while showing dose-dependent antiviral effects in only 16 patients, remains in Phase 1 dose escalation with no proof of sustained viral reservoir reduction or functional cure, yet the company is discussing potential expansion based on preliminary signals—a strategy that could lead to wasted capital if higher doses fail to show improved efficacy or encounter safety issues. Similarly, the type 1 diabetes autoimmune program, despite promising preclinical data, has not yet entered clinical testing, and success in Phase 1 will require demonstrating not just target engagement but meaningful immune modulation in a complex disease where prior immunomodulatory approaches have failed. The PRAME franchise expansion into ovarian and lung cancer relies on signal detection from heterogeneous populations, with Mohammed Dar admitting that lung cancer efforts are still focused on "signal searching," increasing the likelihood of inconclusive or negative data in the second half of 2026. These early-stage bets are being funded by rising R&D expenses, which increased in 2025 due to three Phase 3 trials and are forecast to grow modestly in 2026, potentially pressuring margins if pipeline advancements fail to translate into near-term value inflection points.
Competitive pressures in melanoma are mounting and could erode Immunocore’s differentiated positioning, particularly as alternative therapies advance and reshape the treatment landscape in both uveal and cutaneous melanoma settings. While KIMTRAK currently holds a strong position in frontline uveal melanoma, Ralph Torbay acknowledged the need to see randomized Phase 3 data from competitors like IDEAYA before assessing impact, implicitly recognizing that upcoming readouts could challenge its standard-of-care status. In cutaneous melanoma, the TEBE-AM trial design assumes a control arm where approximately one-third of patients receive checkpoint inhibitor retreatment, but the real-world evolution of therapies—including the growing use of TIL therapy and emerging HLA-matched TCR-T approaches—could elevate control arm outcomes beyond historical assumptions, making it harder to demonstrate a statistically significant overall survival benefit. Mohammed Dar confirmed that TILs are not approved in Europe, where the majority of TEBE-AM enrollment occurs, but did not address how increasing global approval and use of TILs or other immunotherapies might affect the trial’s validity if the control arm improves unexpectedly. Furthermore, the company’s expectation to "defend that price appropriately" in cutaneous melanoma hinges entirely on positive OS data, but if the trial fails or shows only marginal benefit, pricing power in a larger, more competitive market could be severely constrained, undermining the commercial rationale for expansion.

Immunocore Holdings faces growing commercial headwinds in its core KIMTRAK business, as evidenced by slowing sequential quarterly revenue growth in the 4%-7% range, which management explicitly acknowledged is expected to continue declining in 2026 due to high market penetration in major regions. Travis A. Coy noted that the reported 29% year-on-year growth flattered to approximately 20% when normalized for rebate reserves, indicating that underlying demand expansion is weakening faster than topline suggests. With the company now in its fifth year on the market and significant penetration achieved across the U.S. and Europe, the law of large numbers is taking hold, making sustained double-digit growth increasingly difficult without new indication approvals. The reliance on rebate adjustments to mask deceleration raises concerns about the quality of revenue growth, particularly as pricing pressure and payer scrutiny intensify in oncology. Furthermore, while KIMTRAK serves approximately 1,000 metastatic uveal melanoma patients annually, the future addressable population of up to 6,000 patients through ongoing Phase 3 trials remains speculative and contingent on positive trial outcomes—any delay or failure in TEBE-AM or ATOM would significantly delay or diminish this expansion potential, leaving the company overly dependent on a niche indication with limited organic growth runway.
The clinical and regulatory risks associated with Immunocore’s expanding pipeline are underappreciated, particularly given the reliance on early-phase data to justify costly late-stage investments across multiple therapeutic areas. The HIV functional cure program, while showing dose-dependent antiviral effects in only 16 patients, remains in Phase 1 dose escalation with no proof of sustained viral reservoir reduction or functional cure, yet the company is discussing potential expansion based on preliminary signals—a strategy that could lead to wasted capital if higher doses fail to show improved efficacy or encounter safety issues. Similarly, the type 1 diabetes autoimmune program, despite promising preclinical data, has not yet entered clinical testing, and success in Phase 1 will require demonstrating not just target engagement but meaningful immune modulation in a complex disease where prior immunomodulatory approaches have failed. The PRAME franchise expansion into ovarian and lung cancer relies on signal detection from heterogeneous populations, with Mohammed Dar admitting that lung cancer efforts are still focused on "signal searching," increasing the likelihood of inconclusive or negative data in the second half of 2026. These early-stage bets are being funded by rising R&D expenses, which increased in 2025 due to three Phase 3 trials and are forecast to grow modestly in 2026, potentially pressuring margins if pipeline advancements fail to translate into near-term value inflection points.
Competitive pressures in melanoma are mounting and could erode Immunocore’s differentiated positioning, particularly as alternative therapies advance and reshape the treatment landscape in both uveal and cutaneous melanoma settings. While KIMTRAK currently holds a strong position in frontline uveal melanoma, Ralph Torbay acknowledged the need to see randomized Phase 3 data from competitors like IDEAYA before assessing impact, implicitly recognizing that upcoming readouts could challenge its standard-of-care status. In cutaneous melanoma, the TEBE-AM trial design assumes a control arm where approximately one-third of patients receive checkpoint inhibitor retreatment, but the real-world evolution of therapies—including the growing use of TIL therapy and emerging HLA-matched TCR-T approaches—could elevate control arm outcomes beyond historical assumptions, making it harder to demonstrate a statistically significant overall survival benefit. Mohammed Dar confirmed that TILs are not approved in Europe, where the majority of TEBE-AM enrollment occurs, but did not address how increasing global approval and use of TILs or other immunotherapies might affect the trial’s validity if the control arm improves unexpectedly. Furthermore, the company’s expectation to "defend that price appropriately" in cutaneous melanoma hinges entirely on positive OS data, but if the trial fails or shows only marginal benefit, pricing power in a larger, more competitive market could be severely constrained, undermining the commercial rationale for expansion.

Geographical Breakdown of Revenue (2025)

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password